

Liver tropism is key for B cell deletion immunotherapy

1 November 2013

Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding receptors, called Fc receptors, on other immune cells bind anti-CD20 on coated B cells, which induces B cell deletion through a mechanism that is not clearly understood.

In this issue of the *Journal of Clinical Investigation*, Philippe Bousse and colleagues at the Pasteur Institute in Paris described the fate of B [cells](#) in live mice after treatment with anti-CD20 antibodies. Bousse and his group found that B cells circulating through the liver were the first ones depleted after treatment and that B cells in circulation were more susceptible to deletion than those stationary in the spleen or lymph nodes. The researchers used intravital two-photon microscopy to follow B cells in the liver as they halted near specialized Fc receptor-bearing cells called Kupffer cells. The Kupffer cells bound and consumed the anti-CD20-coated B cells.

The study assigns a vital role to liver Kupffer cells in deleting B cells and describes techniques that may be used to improve the effectiveness of anti-CD20 therapy.

More information: The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging, *J Clin Invest*. [DOI: 10.1172/JCI70972](#)

Provided by Journal of Clinical Investigation

APA citation: Liver tropism is key for B cell deletion immunotherapy (2013, November 1) retrieved 2 May 2021 from <https://medicalxpress.com/news/2013-11-liver-tropism-key-cell-deletion.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.